CC-115, a dual mTOR/DNA-dependent protein kinase inhibitor, is now in a clinical trial and is able to revert CD40-mediated resistance to venetoclax and also inhibits BCR signaling in CLL patients with acquired idelalisib resistance (174). Here, MTOR is linked to B-cell chronic lymphocytic leukemia.